LIVZON PHARMAC. GRP H YC1 - Asset Resilience Ratio
LIVZON PHARMAC. GRP H YC1 (LP6) has an Asset Resilience Ratio of 2.93% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See LP6 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how LIVZON PHARMAC. GRP H YC1's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see LP6 total asset value.
Liquid Assets Composition Over Time
This chart breaks down LIVZON PHARMAC. GRP H YC1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read LP6 current and long-term liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €707.99 Million | 2.93% |
| Total Liquid Assets | €707.99 Million | 2.93% |
Asset Resilience Insights
- Limited Liquidity: LIVZON PHARMAC. GRP H YC1 maintains only 2.93% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
LIVZON PHARMAC. GRP H YC1 Industry Peers by Asset Resilience Ratio
Compare LIVZON PHARMAC. GRP H YC1's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for LIVZON PHARMAC. GRP H YC1 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for LIVZON PHARMAC. GRP H YC1.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 5.61% | €1.34 Billion ≈ $1.57 Billion |
€23.99 Billion ≈ $28.04 Billion |
+5.24pp |
| 2024-12-31 | 0.37% | €89.36 Million ≈ $104.47 Million |
€24.46 Billion ≈ $28.59 Billion |
+0.04pp |
| 2023-12-31 | 0.33% | €81.79 Million ≈ $95.62 Million |
€25.04 Billion ≈ $29.28 Billion |
-0.11pp |
| 2022-12-31 | 0.43% | €108.09 Million ≈ $126.37 Million |
€24.87 Billion ≈ $29.07 Billion |
-0.38pp |
| 2021-12-31 | 0.82% | €182.77 Million ≈ $213.68 Million |
€22.37 Billion ≈ $26.16 Billion |
-- |
About LIVZON PHARMAC. GRP H YC1
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, il… Read more